Modality
Multispecific
MOA
KRASG12Di
Target
IL-17A
Pathway
Tau
MGFSGS
Development Pipeline
Preclinical
~Sep 2022
→ ~Dec 2023
Phase 1
~Mar 2024
→ ~Jun 2025
Phase 2
Sep 2025
→ Oct 2025
Phase 2Current
NCT05189886
2,505 pts·MG
2025-09→2025-10·Not yet recruiting
2,505 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-10-036mo agoPh3 Readout· MG
2026-05-212mo awayConference· FSGS
2026-07-264mo awayEMA Filing· FSGS
Trial Timeline
Q42026Q2Q3
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-10-03 · 6mo ago
MG
Conference
2026-05-21 · 2mo away
FSGS
EMA Filing
2026-07-26 · 4mo away
FSGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05189886 | Phase 2/3 | MG | Not yet recr... | 2505 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A |